- Microbiology and Infectious Disease
Intervention of CHI3L1 using anti-CHI3L1 monoclonal antibody or chitinase inhibitor kasugamycin blocks epithelial infection of various SARS-CoV2 variants, suggesting that CHI3L1 is a universal and effective therapeutic target of COVID-19 infection, including recent omicron variants.